InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: None

Wednesday, 01/11/2017 11:43:27 AM

Wednesday, January 11, 2017 11:43:27 AM

Post# of 2099
Regarding the VB-600 series, I think it would be amazing if they could stop the spread of cancer by preventing it from moving. At least that's what I got from the announcement. Hoping VB-111 makes it to market just so the company has the funds to continue its research.

===========
Additional potential milestones may emerge from VBL's innovative pipeline. Our continuing research into the mechanisms of cancer biology led us to identify a cell surface protein which is involved in the motility of certain cancer cells and immune cells. Serving as the basis for VBL's "VB-600" series, our researchers have developed antibodies against this novel target, which may have potential in clinical applications. We intend to provide additional data about this target protein in first half of 2017.
===========
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News